Triglycerides (TGs) are now considered an independent risk factor for cardiovascular disease (CVD). When TGs are elevated, lipoprotein metabolism is altered, which increases CVD risk. Patients with elevated TGs and low high-density lipoprotein are at particularly high risk of CVD. TGs are often associated with other CVD risk factors, such as obesity, insulin resistance, diabetes mellitus, low HDL cholesterol, lifestyle factors, and changes in lipoprotein size and density. Elevated TGs remain an independent risk even when controlling for the other factors and are a greater risk for women than men. Treatment of elevated TGs in clinical trials has been shown to reduce CVD events, cardiac deaths, and total mortality.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
References and Recommended Reading
Jeppesen J, Hein HO, Suadicani P, et al.: Triglyceride concentration and ischemic heart disease. Circulation 1998, 97:1029–1036.
Hopkins PN, Wu LL, Hunt SC, Brinton EA: Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005, 45:1003–1012.
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Non-fasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in the general population. JAMA 2007, 298:299–306.
Bansal S, Buring JE, Rifai N, et al.: Fasting compared with non-fasting triglycerides and the risk of future cardiovascular events in women. JAMA 2007, 298:309–316.
Tirosh A, Rudich A, Shochat T, et al.: Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007, 147:377–385.
Patel A, Barzi F, Jamrozik K, et al.; Asia Pacific Cohort Studies Collaboration: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110:2678–2686.
Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991, 11:2–14.
Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213–219.
Sarwar N, Danesh J, Eiriksdottir G, et al.: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007, 115:450–458.
Genest, JJ, Martin-Munley, SS, McNamara, JR, et al.: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992, 85:2025.
Ginsberg HN: New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137–2142.
St. Pierre AC, Ruel IL, Cantin B, et al.: Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001, 104:2295–2299.
Otvos JD, Jeyarajah EJ, Cromwell WC: Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90:22i–29i.
Brehm A, Pfeiler G, Pacini G, et al.: Relationship with serum lipoprotein ratios and insulin resistance in obesity. Clin Chem 2004, 50:2316–2222.
Gaziano JM, Hennekens CH, O’Donnell CJ, et al.: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. 1997, 96:2520–2525.
Austin MA, King MC, Vranizan KM, et al.: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495–506.
Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998, 81:18B–25B.
Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit of niacin. J Am Coll Cardiol 1986, 8:1245–1255.
Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37–45.
Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585–1591.
FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.
Miller M, Cannon CP, Murphy SA, et al.: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724–730.
Carlson LA, Rosenhammar G: Reduction of mortality in the Stockholm Ischemic Heart Disease Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418.
Superko HR, King S: Is lowering low-density lipoprotein an effective strategy to reduce cardiac risk? Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008, 117:560–568.
National Cholesterol Education Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.
Sharett AR, Ballantyne CM, Coady SA, et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-1 and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001, 104:1108–1113.
El Harchaoui K, van der Steeg WA, Stroes ESG, et al.: Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women. The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 49:547–553.
Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004, 27:2444–2449.
Haim M, Benderly M, Brunner D, et al., for the BIP Study Group: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) registry. Circulation 1999, 100:475–482.
Ingelsson E, Schaefer EJ, Contois JH, et al.: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776–785.
Ridker PM, Rifai N, Cook NR, et al.: Non-HDL cholesterol, apoplipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294:326–333.
McBride PE: Triglycerides and risk for coronary heart disease. JAMA 2007, 298:336–338.
Cui Y, Blumenthal RS, Flaws JA, et al.: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001, 161:1413–1419.
Kontush A, Chapman MJ: Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3:144–153
Tribble DL, Holl LG, Wood PD, Krauss RM: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1999, 93:189–199.
Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69–75.
Sulkes D, Brown BG, Krauss RM, et al.: The Editors Roundtable: Expanded versus standard lipid panels in assessing and managing cardiovascular risk. Am J Cardiol 2008, 101:828–842.
Mukamal KJ, Mackey RH, Kuller LH, et al.: Alcohol consumption and lipoprotein subclasses in older adults. J Clin Endocrinol Metab 2007, 92:2559–2566.
Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.
Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.
Brown BG, Brockenbrough A, Zhao XQ, et al.: Very intense lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation 1998, 98(Suppl I):I–635.
Azen SP, Mack WJ, Cashin-Hemphill L, et al.: Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996, 93:34–41.
Carlson LA: Nicotinic acid: the broad-spectrum lipid drug: a 50th anniversary review. J Intern Med 2005, 258:94–114.
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events. Available at http://www.clinicaltrials.gov/ct/show/NCT00120289. Accessed on May 10, 2008.
Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996, 275:128–133.
Guerin M, Egger P, Le Goff W, et al.: Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type iib hyperlipidemia. J Clin Endocrinol Metab 2002, 87:4991–5000
Davidson MH, Ma P, Stein EA, et al.: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002, 89:268–275.
About this article
Cite this article
McBride, P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 10, 386–390 (2008). https://doi.org/10.1007/s11883-008-0060-9
- Atherogenic Lipoprotein
- Helsinki Heart Study
- Coronary Drug Project
- Familial Atherosclerosis Treatment Study